Mixed incontinence: current evidence and future perspectives.
The epidemiology and treatment of mixed incontinence has received relatively little attention. However, mixed incontinence--defined as the combination of stress and urge incontinence accounts for approximately 33% of all cases of incontinence in women. The condition often responds poorly to treatment, either pharmacologic or surgical. Potential pharmacologic approaches for mixed incontinence include antimuscarinic agents, estrogen replacement therapy (for postmenopausal women), and dopamine, serotonin, or norepinephrine reuptake inhibitors. In a large-scale, multinational, placebo-controlled, clinical trial, the antimuscarinic agent tolterodine significantly reduced incontinence episodes in women with mixed symptoms. The benefits of tolterodine continued to increase during the 8 weeks of the trial and extended to additional end points, including frequency, urgency, and urge incontinence. A limited number of studies have examined the use of estrogen for mixed incontinence and have produced conflicting results. Duloxetine oxalate, a combined serotonin/norepinephrine reuptake inhibitor, has shown great promise in animal studies, as well as in phase 2 and 3 clinical trials. This agent is the first to demonstrate efficacy as a sole therapy for stress incontinence and has exhibited favorable effects on bladder capacity, suggesting possible benefits in mixed incontinence. Only five studies (two of which were conducted during the 1980s) have specifically examined the use of surgery for the treatment of mixed incontinence; the cure rates reported have varied. The current body of information supports use of an antimuscarinic agent as initial therapy for mixed incontinence, although long-term trials are needed to shed more light on the duration of benefit.
Khullar
Vik
V
Department of Urogynaecology, Imperial College London, London, UK.
Cardozo
Linda
L
Dmochowski
Roger
R
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003408:Cresols / Q000627:therapeutic use*; D000068736:Duloxetine Hydrochloride; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013997:Time Factors; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000601:surgery; D014550:Urinary Incontinence, Stress / Q000188:drug therapy / Q000453:epidemiology; D053202:Urinary Incontinence, Urge / Q000188:drug therapy / Q000453:epidemiology
D018759:Adrenergic Uptake Inhibitors; D001559:Benzhydryl Compounds; D003408:Cresols; D000068736:Duloxetine Hydrochloride; D004967:Estrogens; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D000068737:Tolterodine Tartrate